Clinical trial
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
NCT00422123 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00422123 |
|---|---|
| Title | Phase 3 /Seroquel SR Acute Mania Monotherapy - US |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate (Seroquel) SR |
| Enrollment | 447 |
| Start date | Jan 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jan 15, 2007 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: